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Abstract 
Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis through the 
suppression of the mammalian target of rapamycin complex 1 (mTORC1), a critical regulator 
of muscle growth. The purpose of this investigation was to determine the role of AMPKα1 
catalytic subunit on muscle cell size control and adaptation to muscle hypertrophy. We found 
that AMPKα1 (-/-) primary cultured myotubes and myofibers exhibit larger cell size 
compared to control cells in response to chronic Akt activation. We next subjected the 
plantaris muscle of AMPKα1 (-/-) and control mice to mechanical overloading in order to 
induce muscle hypertrophy. We observed significant elevations of AMPKα1 activity in the 
control muscle at days 7 and 21 following the overload. Overloading-induced muscle 
hypertrophy was significantly accelerated in AMPKα1 (-/-) mice than in control mice (+32% 
vs +53% at day 7 and +57% vs +76% at day 21 in control vs AMPKα1 (-/-) mice, 
respectively). This enhanced growth of AMPKα1-deficient muscle was accompanied by 
increased phosphorylation of mTOR signaling downstream targets and decreased 
phosphorylation of eukaryotic elongation factor 2. These results demonstrate that AMPKα1 
plays an important role in limiting skeletal muscle overgrowth during hypertrophy through 
inhibition of mTOR signaling pathway. 
 
 
Key Words : muscle functional overload, protein synthesis, mTOR-S6K signaling. 
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Introduction 
The 5'-AMP-activated protein kinase (AMPK) is a sensor of cellular energy homeostasis well 
conserved in all eukaryotic cells (1). AMPK is activated by metabolic stresses that elevate the 
AMP/ATP ratio by lowering ATP production following inhibition of mitochondrial oxidative 
phosphorylation (e.g., metabolic poisons) or increasing ATP consumption (e.g., muscle 
contraction). Once activated, at the level of the individual cell, AMPK switches on catabolic 
pathways (such as fatty acid oxidation and glycolysis) and switches off ATP-consuming 
pathways (such as lipogenesis) with short-term effects on phosphorylation of regulatory 
proteins and long-term effects on gene expression. Mammalian AMPK is a heterotrimeric 
enzyme complex consisting of one catalytic subunit (α) and two regulatory (β and γ) subunits 
and isoforms of all three subunits have been identified (α1, α2, β1, β2, γ1, γ2 and γ3). The 
phosphorylation of a conserved threonine residue (Thr172) within the kinase domain of the 
α−catalytic subunit is absolutely required for AMPK activation. Three upstream kinases have 
been recently identified and correspond to the tumor suppressor LKB1/STK11 kinase, 
CaMKKβ (Ca2+/calmodulin-dependent protein kinase kinase β) and TAK1 (TGFβ-activated 
kinase-1, a member of the mitogen-activated protein kinase kinase family) (2). Binding of 
AMP to the γ-subunits leads to allosteric activation of AMPK as well as to enhanced 
phosphorylation of Thr172 by inhibiting its dephosphorylation by protein phosphatase(s) (3). 
In skeletal muscle, AMPK is activated by multiple stimuli including hypoxia, osmotic stress, 
endurance exercise and electrically-stimulated contraction (4). AMPK activation causes 
metabolic changes that assist muscle cells in making chronic adaptations to energy 
deprivation, such as an increase in oxidative capacity via increased mitochondrial biogenesis, 
enzyme expression and uptake of nutrients such as glucose and fatty acids. Importantly, some 
of these metabolic adaptations seem to preferentially occur through the regulation of 
AMPKα2 but not via AMPKα1 isoform (5-7). These results suggest distinct physiological 
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roles for α1- and α2-containing AMPK complexes in the regulation of skeletal muscle 
adaptations. Activation of the various AMPK complexes may depend on the specificity of 
upstream kinase for α-catalytic subunits phosphorylation. Indeed, in LKB1-deficient muscle, 
AMPKα2 activation is severely blunted whereas AMPKα1 activation is substantially induced 
in response to contraction, indicating discordant regulation of α1- and α2-containing AMPK 
complexes (8). Similar results have been obtained in LKB1-deficient heart in response to 
ischemia or anoxia (9). 
One consequence of endurance exercise training is a partial fiber type transition towards a 
slow-oxidative phenotype associated with mitochondrial biogenesis but no growth. In 
contrast, resistance exercise training mainly stimulates muscle protein synthesis and increases 
muscle fiber volume resulting in hypertrophy. Since protein synthesis can account for up to 
30-50% of the cellular energy expenditure, a reduction in protein synthesis seems an efficient 
mechanism to save energy. Activation of skeletal muscle AMPK during conditions of 
energetic stress is thought to act as a negative regulator of protein synthesis and may therefore 
modulate skeletal muscle mass and hypertrophy (10, 11). AMPK activation has been also 
reported to inhibit protein synthesis associated with hypertrophy in cardiac muscle (12, 13). 
Several lines of evidence suggest that AMPK reduces both the initiation and the elongation of 
ribosomal peptide synthesis (14). One potential mechanism is through AMPK-mediated 
phosphorylation of the eukaryotic elongation factor 2 (eEF-2) kinase at Ser
398
 (15), leading to 
increase Thr
56 
phosphorylation and inactivation of eEF2, a key component in protein 
elongation (16). Another mechanism is linked to the ability of AMPK to block the activation 
of the mammalian target of rapamycin (mTOR) signaling pathway (10, 17-20). While AMPK 
is active in response to nutrient deprivation and inactive under nutrient-rich conditions, 
mTOR is activated in the inverse pattern. mTOR is part of two distinct multiprotein 
complexes, mTORC1 (containing mTOR, mLST8 and Raptor) which is responsible for cell 
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growth and mTORC2 (containing mTOR, mLST8, protor and Rictor) which is important in 
glucose metabolism and cytoskeletal organization (20, 21). mTORC1 is activated in skeletal 
muscle by a variety of anabolic signals, such as resistance exercise, insulin, growth factors 
and amino acids, to stimulate protein synthesis and hence muscle cell growth and hypertrophy 
(17, 22, 23). It has been well established that insulin primarily regulates mTOR through PI3K-
Akt signaling to stimulate cell growth (20). It was recently shown that Rag GTPases play a 
primary role in amino acids signaling to mTOR (24). The mTORC1 signaling pathway 
contains multiple potential sites for regulatory integration with AMPK (10, 25). AMPK 
phosphorylates and activates the tuberous sclerosis complex 2 (TSC2) kinase, which 
subsequently inactivates the G-protein Rheb thereby blocking activation of mTOR (25, 26). 
Recently, it has been shown that AMPK-dependent phosphorylation of Raptor leads also to 
the inhibition of mTORC1 (27). Skeletal muscle ribosomal S6 kinase (p70S6K) and 
eukaryotic initiation factor (eIF)-4E binding protein 1 (4E-BP1) are well-characterized 
downstream components of mTORC1 signaling pathway and phosphorylation of these 
proteins have been associated with increased muscle mass following hypertrophic stimuli. 
Conversely, deletion of p70S6K reduces muscle cell size to the same extent as that observed 
with the mTORC1 inhibitor rapamycin. Interestingly, the suppression of the p70S6K kinases 
is sufficient to trigger an energy stress response associated with AMPK activation, leading to 
coordinated changes in cell growth and metabolic rates (28). 
A strong negative correlation has been reported between the degree of AMPK 
phosphorylation and the degree of hypertrophy in overloaded plantaris (PLN) muscles, 
implicating AMPK as a potentially important negative regulator of overload-induced skeletal 
muscle hypertrophy (29). AMPK phosphorylation was negatively correlated with the amount 
of phosphorylated p70S6K at the mTOR-specific Thr
389
 residue and it was postulated that 
AMPK inhibited p70S6K phosphorylation via its reported suppression of mTOR pathway (10, 
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28, 30). It has recently been reported that continuous AICAR (5-aminoimidazole-4-
carboxamide-1-β-D-ribofuranoside) infusion inhibits overloading-induced muscle 
hypertrophy (31). Interestingly, McGee et al. have shown that the hypertrophy produced by 
overload was associated with a marked activation of AMPKα1 in both WT and LKB1-
deficient mice and they proposed that AMPKα1 might play an important role in the regulation 
of skeletal muscle growth (32). 
Therefore, the aim of this investigation was to examine the potential role of AMPKα1 
catalytic subunit in the size control of muscle cells in unstimulated and in response to 
hypertrophic stimuli. For this purpose, we analyzed the size of AMPKα1-deficient muscle 
cells in response to cell growth stimulation and determined the degree of muscle hypertrophy 
following muscle overload in AMPKα1-deficient mice. 
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Methods 
Animals 
The generation of AMPKα1 (-/-) mice has been described previously (33). AMPKα1 (-/-) and 
WT mice (20-26 weeks old) were maintained on a 12h:12h light-dark cycle and received 
standard rodent chow and water ad libitum. Genotyping was performed by PCR using DNA 
from a tail-piece (forward 5’-AGCACAGTACCTGGTATCTTATAGG-3’ and reverse 5’-
GGACTTATTACTAAACAGACCTCTG-3’ primers for WT allele; forward 5’-
ACCAGAAGCGGTGCCGGAAAGCTGG-3’ and reverse 5’-
TGTAGTCGGTTTATGCAGCAACGAG-3’ primers for AMPKα1 deleted allele). All 
procedures were performed in accordance with the principles
 
and guidelines established by 
the European Convention for the
 
Protection of Laboratory Animals. 
Cell culture and adenovirus infection 
Primary muscle cell cultures were derived from gastrocnemius and tibialis anterior (TA) 
muscles of 4-week-old mice as described (34). Myotubes at day 2 of differentiation were 
infected with an adenovirus expressing GFP or a constitutively active Akt, NH(2)-terminally 
myristoylation signal-attached Akt (MyrAkt) (28) at the multiplicity of infection of 75 and 
incubated for 2 days in DMEM/Ham’s F12 medium containing 2% horse serum. Then, bright-
field images were taken and analysed using Metamorph software (version 7.04, Molecular 
Devices). The diameter of at least 400 myotubes was measured at day 4 of differentiation in a 
region where myonuclei were absent and diameter was constant. Cells were harvested the 
same day for western blot analysis. 
In vivo transfection of mouse skeletal muscle by electroporation 
Hyalurodinase (0.4 U) was injected along the TA muscle length and after two hours, animals 
anaesthetized with xylazine-ketamine were injected with 15 µg of plasmids encoding GFP or 
MyrAkt. Electrical pulses were then applied by two stainless steel spatula placed on each side 
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of the muscle (130 Volts/cm, 6 pulses, 100 ms interval). Muscles were removed and analyzed 
10 days later. 
Bilateral synergist ablation model 
The bilateral synergist ablation model
 
was used to induce hypertrophy of the plantaris (PLN) 
muscle by functional
 
overload in AMPKα1 (-/-) and control mice, as previously described 
(35). On the day of surgery (D0), animals were anaesthetized with xylazine-ketamine and 
maintained in the surgical plane. A longitudinal incision
 
on the dorsal aspect of the lower 
hindlimb was made exposing
 
the gastrocnemius muscle. The tendons of the gastrocnemius 
and
 
soleus muscles were isolated and used to guide in the excision
 
of these muscles without 
disturbing the PLN muscle. The overlying skin was closed using sterile suture and the mice 
were allowed to recover in a temperature-controlled area prior to being returned to their cages. 
Animals were monitored for signs of pain or post-operative infection. 
Tissue collection 
Animals were anaesthetized with xylazine-ketamine and overloaded TA muscles or 
transfected PLN muscles of both legs were removed, cleaned and precisely weighed. Muscles 
were then frozen in liquid nitrogen for protein extraction or in liquid nitrogen-chilled 
isopentane for preservation of fiber morphology and stored at -80°C until processed. 
Protein extraction, western blotting and AMPK activity assays 
Total protein extracts from PLN muscles and muscle cells samples were
 
obtained as described 
previously (8). Fifty µg
 
of protein were subjected to SDS-PAGE and transferred to
 
nitrocellulose membrane. Blots were probed with antibodies against total AMPKα1, 
AMPKα2 (a kind gift from G. Hardie, University of Dundee, Scotland), phosphorylated 
forms of eEF2 (Thr56), S6 (Ser235/236), p70S6K (Thr389) and 4E-BP1 (Thr37/46) (Cell 
Signaling). Measure of AMPK α1 and α2 activities was performed as described previously 
(36). 
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Immunohistochemistry 
Serial transverse sections (12-16 µm thick) were cut from TA and PLN muscles in a cryostat 
microtome (Leica, Germany) maintained at -25°C and stained with hematoxylin and eosin to 
visualize tissue morphology. We analyzed fiber size by incubating muscle sections with 
mouse anti-dystrophin Dys2 (Novocastra) and anti-HA (Roche) antibodies and staining with 
Hoechst dye. The fiber cross-sectional area (CSA) was determined using Metamorph software 
(version 7.04, Molecular Devices).  
Statistical analysis 
Results are expressed as means ± SD. We used Student’s
 
t test for unpaired data. Differences 
were considered significant if P < 0.05. 
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Results 
Cell size control in AMPKα1-deficient muscle cells 
In order to examine the role of AMPKα1 in the control of muscle cell size, we isolated and 
analyzed primary muscle cells from AMPKα1 (-/-) and control mice. Western blotting 
analysis revealed that AMPKα1 protein was undetectable in AMPKα1 (-/-) myotubes and the 
levels of AMPKα2 protein were similar between AMPKα1 (-/-) and WT myotubes (Figure 
1A). The deletion of AMPKα1 caused a 15% increase in myotube diameter (Figure 1B). 
Furthermore, myotubes size distribution for AMPKα1 (-/-) cells showed fewer small–
diameter myotubes and increased number of large-diameter myotubes compared to WT cells 
(Figure 1C). To evaluate the functional consequence of AMPK deletion on mTOR-pathway-
mediated hypertrophy, we introduced WT and AMPKα1 (-/-) muscle cells with an adenovirus 
expressing MyrAkt, an established way of activating the mTOR signaling pathway (22, 23). 
We found that the hypertrophic action of MyrAkt was two-fold higher in AMPKα1 (-/-) 
myotubes compared to WT cells (Figure 1B). The diameter of myotubes increased 
significantly by 29% in AMPKα1 (-/-) cells vs 16% in WT cells. Furthermore, the degree of 
hypertrophy (determined by the shift on the right of the cumulated percentage of myotube size 
distribution) was greater for AMPKα1 (-/-) cells in response to MyrAkt overexpression 
(Figures 1C). Finally, we observed an increase in p70S6K phosphorylation (+39%) in 
AMPKα1 (-/-) myotubes introduced with MyrAkt, consistent with a negative action of 
AMPKα1 on mTOR signaling network (Figure 1D). 
MyrAkt-induced cell growth in AMPKα1-deficient muscle 
In order to gain further insights into the role of AMPKα1 in the regulation of muscle cell 
growth in vivo, we transfected AMPKα1 (-/-) and control TA muscles with a plasmid 
expressing MyrAkt or GFP by electroporation. The hypertrophic action of MyrAkt was 
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significantly higher in AMPKα1 (-/-) skeletal muscle fibers compared to WT fibers (Figure 
2). Indeed, the cross sectional area of AMPKα1 (-/-) myofibers increased significantly by 
125% compared to 68% for WT myofibers (Figure 2). 
Changes in AMPK activity and expression following overload-induced hypertrophy 
Since robust activation of AMPKα1 has recently been reported during muscle hypertrophy 
(32), we examined the overloading-induced muscle growth in mice lacking AMPKα1. 
Following 7 days of overload, AMPKα1 activity was markedly increased in the PLN of WT 
mice (+446%; Figure 3A) and remained significantly higher at D21 compared to D0 (+106%; 
Figure 3A), although it was significantly lower compared to D7 (Figure 3A). Coincidentally, 
AMPKα1 expression increased dramatically at D7 (+441%; Figure 4) and at D21 (+336%; 
Figure 4) in WT mice. In the PLN muscles of the AMPKα1 (-/-) mice, AMPKα1 activity was 
ablated and only background counts were detected (Figure 3A). The absence of AMPKα1 
expression in PLN muscle of AMPKα1 (-/-) mice was confirmed by western blot analysis 
(Figure 4). Loss of AMPKα1 resulted in an increase in the basal level of AMPKα2 activity 
(Figure 3B). In contrast to AMPKα1 activity, AMPKα2 activity was reduced in both WT (-
67%; Figure 3B) and AMPKα1 (-/-) mice at D7 (-65%; Figure 3B). The activity of AMPKα2 
at D21 for both WT and AMPKα1 (-/-) mice returned to a value closed to the basal level of 
WT mice (Figure 3B). AMPKα2 expression was unaffected in PLN from AMPKα1 (-/-) and 
WT mice at D7, but significantly decreased in AMPKα1 (-/-) mice at D21 (Figure 4). 
Muscle mass and myofiber size in AMPKα1-deficient mice 
The ratio of PLN mass to tibia length was significantly lower in AMPKα1 (-/-) mice 
compared to WT mice (Figure 5A). Myofiber size distribution of AMPKα1 (-/-) PLN exhibits 
increased number of small myofibers and fewer large myofibers compared to WT PLN 
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(Figures 5B). Morever, the number of nuclei per fiber in AMPKα1 (-/-) mice was smaller (-
22%) compared to WT mice (P<0.01). 
Muscle mass and myofiber size following overload-induced hypertrophy 
After 7 and 21 days of overload, the degree of muscle hypertrophy (determined by PLN mass 
to tibia length) produced by bilateral functional overload is more pronounced in AMPKα1 (-/-
) mice than in WT mice (Figure 5A). PLN mass of AMPKα1 (-/-) mice was increased by 53% 
(P<0.01) and 76% (P<0.01) at D7 and D21 respectively, whereas PLN mass of WT mice was 
significantly increased by 32% (P<0.05) and 57% (P<0.01) during the same period (Figure 
5A). The degree of hypertrophy, as determined by the shift of myofibers size distribution 
between D0 and D7 and between D0 and D21, was more pronounced in AMPKα1 (-/-) mice 
than in WT mice (Figures 5B and 5C). Furthermore, analysis of myofiber size distribution 
shows a clear shift to fibers with larger size at D21 compared to D0 and D7 for both 
AMPKα1 (-/-) and WT mice (Figures 5C and 5D). 
mTOR signaling in AMPKα1 (-/-) mice following overload-induced hypertrophy 
After 7 days of overload, we observed a significant increase of p70S6K phosphorylation in 
both WT and AMPKα1 (-/-) mice (Figure 6A). This increase in p70S6K phosphorylation 
between D0 and D7 was greater for AMPKα1 (-/-) mice compared to WT mice (Figure 6A). 
In addition, the enhanced phosphorylation p70S6K (Figure 6A) was still present at D21 in 
AMPKα1 (-/-) mice, whereas it returned to basal level in WT mice (Figure 6A). 
Consequently, phosphorylation of p70S6K was significantly higher in AMPKα1 (-/-) mice 
compared to WT mice at D21. Following 7 and 21 days of overload, phosphorylation of S6 
was also significantly increased in AMPKα1 (-/-) and WT mice (Figure 6A). The deletion of 
AMPKα1 caused an enhanced increase in 4E-BP1 phosphorylation at D7 (P<0.001) and D21 
(P=0.051) (Figure 6B). Finally, phosphorylation of eEF2 was significantly higher in 
AMPKα1 (-/-) mice compared to WT mice at D0 (Figure 6B). Furthermore, we observed a 
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significant increase in phosphorylation of eEF2 in response to 21 days of overload in WT 
mice (Figure 6B), whereas phosphorylation of eEF2 significantly decreased in AMPKα1 (-/-) 
mice (-59%; P<0.01; Figure 6B). 
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Discussion 
The major aim of this study was to investigate the role of AMPKα1 in the control of muscle 
cell size and growth. Previous studies have demonstrated that AMPK integrates fuel sensing 
with cell growth control and contributes to the atrophic adaptations of p70S6K-deficient 
muscle (28). Here, we show that the size of AMPKα1-deficient myotubes is larger than 
AMPKα1-expressing control cells, demonstrating a unique role for AMPKα1 in the control 
of cell size. However unexpectedly, the mass of PLN muscle in basal state was significantly 
lower in AMPKα1 (-/-) mice compared to WT mice. One potential reason for this lower 
muscle mass in AMPKα1 (-/-) mice is a reduced ATP production, thus providing less energy 
for protein synthesis and growth. However, this should not be the case in cultured AMPKα1 
(-/-) myotubes as their size is larger than AMPKα1-expressing control myotubes. 
Interestingly, the role for AMPKα1 isoform in the control of muscle energy balance has been 
recently challenged and data obtained from LKB1-deficient muscles suggest that skeletal 
muscle metabolic adaptation is rather dependent on AMPKα2 than on AMPKα1 activation 
(32). Furthermore, we previously reported that the lack of AMPKα2 isoform was associated 
with a lower ATP content in skeletal muscle (33), indicating that remaining AMPKα1 
isoform was not able to compensate for the loss of AMPKα2 isoform to maintain muscle 
energy balance. Lastly, it should be also noted that in AMPKα1 (-/-) PLN muscle, AMPKα2 
activity is increased compared to WT muscle in the basal state, resulting probably in a 
compensatory response for ATP production. Another hypothesis for the lower basal PLN 
mass in AMPKα1 (-/-) mice is a role for satellite cells that are partly responsible for postnatal 
muscle growth (37, 38). Although AMPK function in satellite cells has not been investigated 
yet, an impaired or reduced satellite cell proliferation in the absence of AMPKα1, as 
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illustrated by the lower number of nuclei per fiber in AMPKα1 (-/-) PLN muscle, might 
explain this unexpected result (39). 
Recent evidence supports the existence of distinct regulatory pathways and functions for 
AMPKα1 and AMPKα2 isoforms. The overloading-induced hypertrophy is associated with a 
significant increase in AMPKα1 expression and activity in WT muscle, whereas the activity 
of AMPKα2 is reduced at D7 and returns close to basal value at D21 for both WT and 
AMPKα1 (-/-) muscles. This marked activation of AMPKα1 following 7 and 21 days of 
chronic overload has been suggested to limit muscle mass growth (32). AMPKα2 appears to 
be preferentially activated in response to acute exercise (40-46) or by endurance training 
program (47) whereas low intensity contraction stimulation activates AMPKα1 in skeletal 
muscle (48). Interestingly, it has been shown that only AMPKα1 activation is required for 
stimulation of glucose uptake by twitch contraction (49). In this condition, AMPKα1 
activation was not accompanied by an
 
increase in AMP level and AMP/ATP ratio, suggesting 
that AMPKα1 activation induced by low-intensity contraction is regulated by an AMP-
independent (48) and/or LKB1-independent mechanism. Accordingly, LKB1 appears to be 
essential for AMPKα2 activity in different muscle types whereas AMPKα1 activity is only 
partially affected in LKB1-deficient skeletal muscle (8, 32). Recently, it has been 
demonstrated that skeletal muscle hypertrophy is normal in response to chronic mechanical 
overload in the absence of LKB1 due to significant increase in the activation of the AMPKα1 
isoform (32). One mechanism for AMPKα1 activation could be through the Ca2+/calmodulin-
dependent protein kinase kinases (CaMKKs) and the TGFβ-activated protein kinase (TAK-1) 
(32). 
In the present study, we provide genetic evidence for a negative role for AMPKα1 in the 
control of mTOR signaling and growth in muscle cells. The hypertrophic action of MyrAkt, an 
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effector known to stimulate skeletal muscle protein synthesis through activation of mTOR 
signaling, was enhanced in primary cultured myotubes and myofibers deleted for AMPKα1. 
However, the effect of rapamycin or Torin1 (potent allosteric mTORC1 inhibitors) in 
AMPKα1-deficient muscle would bring additional evidence for a negative role on mTOR 
signaling. We also show that muscle hypertrophy produced by functional overload is greater 
in mice deleted for AMPKα1 catalytic subunit compared to WT mice. A strong correlation 
between increased AMPK activity in the PLN muscle from old rats and impaired overload-
induced skeletal muscle hypertrophy has been recently reported (29). AMPK phosphorylation 
was negatively correlated with the amount of p70S6K phosphorylated at the mTOR-specific 
Thr
389
 residue in response to 7 days of chronic overload, supporting the notion that AMPK 
inhibited p70S6K phosphorylation in skeletal muscle via suppression of mTOR (10, 30). 
Conversely, enhanced hypertrophy in AMPKα1 (-/-) muscle is associated with higher 
activation of mTORC1 signaling pathway, as determined by increased phosphorylation of 
p70S6K and 4E-BP1 at D7 and D21. These results are in accordance with studies showing the 
importance of mTOR-p70S6K signaling and 4E-BP1 phosphorylation in the hypertrophic 
response of chronically-overloaded muscle (17, 19, 30). In addition, we observed a decrease 
in eEF2 phosphorylation in AMPKα1 (-/-) muscle following 7 and 21 days of overload, 
indicating an improvement of protein elongation. Thus, in the absence of AMPKα1, 
unphosphorylated (active) eEF2 levels are higher in response to chronic overload with a 
parallel increase in mTORC1 signaling leading to a greater muscle hypertrophy. Hence, 
AMPKα1 behaves as a negative effector required to limit mTORC1 activity and to inhibit 
overgrowth of skeletal muscle in response to hypertrophic stimuli. 
In conclusion, we demonstrate an essential role for AMPKα1 in the adaptation of skeletal 
muscle growth to hypertrophy. The major new findings of this study are as follows: (1) 
muscle cells hypertrophy in vitro and in vivo is more pronounced in mice deleted for 
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AMPKα1 catalytic subunit compared to control mice; (2) phosphorylation of mTORC1 
signaling downstream targets, controlling protein synthesis, is enhanced in the absence of 
AMPKα1 following chronic overload and is associated with a greater muscle hypertrophy. 
Our study provides important knowledge on the role of AMPK in the molecular mechanisms 
underlying the cell size control that may open new avenues of intervention against age-related 
skeletal muscle atrophy. Although resistance training can increase muscle size and strength, 
the myogenic response to exercise and the capacity for muscle hypertrophy in older humans is 
limited. The prevention of sarcopenia, which is the consequence of a reduction of protein 
synthesis and an increase in muscle protein degradation, would provide an obvious clinical 
benefit.  
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Figure legends 
Figure 1 : Cell size control in primary muscle cells lacking AMPKα1. (A) Primary muscle 
cells isolated from AMPKα1 (-/-) and control mice were differentiated into myotubes and 
AMPKα1 and AMPKα2 protein content was assessed by western blot analysis. A 
representative immunoblot of AMPKα1 (upper panel) and AMPKα2 (lower panel) is shown. 
(B) Size of WT and AMPKα1 (-/-) myotubes transduced with 75 moi GFP and MyrAkt 
adenoviruses as indicated. Results are presented as a percentage of WT muscle cells 
transduced with GFP adenovirus. Representative bright-field images of myotubes transduced 
with GFP and MyrAkt adenoviruses are shown in the upper part of the figure. (C) Frequency 
distribution of size of WT and AMPKα1 (-/-) myotubes transduced with GFP and MyrAkt 
adenoviruses. Size of myotubes was determined with the diameter of at least 400 myotubes 
measured in a region where myonuclei were absent and diameter was constant. Data from five 
experiments on two different cultures are shown in B and C. Results are represented as means 
± SD in B and C. Different from GFP cells of the same genotype in B : 
$
P<0.05, 
$$
P<0.01; 
Different for the same conditions of infection in B : 
#
P<0.05, 
##
P<0.01. WT myotubes 
different from AMPKα1 (-/-) myotubes both transduced with GFP adenovirus in C : #P<0.05, 
##
P<0.01, 
###
P<0.001. WT myotubes different from AMPKα1 (-/-) myotubes both transduced 
with MyrAkt adenovirus in C : 
§
P<0.05, 
§§§
P<0.001. (D) Thr389 p70S6K phosphorylation was 
determined 2 days after infection. Representative immunoblot is shown in the upper part of 
the figure. Protein content is expressed in arbitrary units relative to GFP infected cells for 
each genotype. Results are represented as means ± SD. Different from GFP cells of the same 
genotype : 
$
P<0.05, 
$$
P<0.01. 
 
Figure 2 : Change in cross-sectional area of WT and AMPKα1 (-/-) myofibers in tibialis 
anterior muscle transfected with MyrAkt. Changes in size of WT and AMPKα1 (-/-) 
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myofibers overexpressing MyrAkt represented as percent changes to non-transfected 
myofibers. Detection of MyrAkt (HA-tagged MyrAkt) transfected myofibers was realized by 
immunostaining with anti-HA antibody. A representative image showing positive cells 
marked with a star is presented in the upper part of the figure. The fiber cross-sectional area 
of 180 fibers was determined from at least 3 differents muscle areas of 4 animals in each 
group. Results are represented as means ± SD. Different from WT : 
#
P<0.05. 
 
Figure 3 : AMPK activity in plantaris muscle following overload-induced hypertrophy in 
WT and AMPKα1 (-/-) mice. (A) AMPKα1 and (B) AMPKα2 activity (mU/mg) measured 
using immunoprecipitate kinase assays in plantaris muscle following 0 (D0), 7 (D7) and 21 
(D21) days of overload. Results are represented as means ± SD, n = 6 for each genotype. 
Different from Day 0 : 
$
P<0.05; 
$$
P<0.01, 
$$$
P<0.001; Different from Day 7 : 
§
P<0.05, 
§§§
P<0.001; Different from WT : 
#
P<0.05; 
##
P<0.01. 
 
Figure 4 : AMPK expression in plantaris muscle following overload-induced 
hypertrophy in WT and AMPKα1 (-/-) mice. AMPKα1 and AMPKα2 expression 
measured by western blot analysis in plantaris muscle following 0 (D0), 7 (D7) and 21 (D21) 
days of overload. Quantification by densitometry of immunoblots is reported alongside the 
figure. Results are represented as means ± SD, n = 4 for each genotype. Different from Day 0 
: 
$$$
P<0.001; Different from WT : 
##
P<0.01. 
 
Figure 5 : Muscle mass and fiber size in response to overload-induced hypertrophy in 
WT and AMPKα1 (-/-) mice. (A) Mass (g) of plantaris muscles normalized to the tibia 
length (cm) following 0 (D0), 7 (D7) and 21 (D21) days of overload is shown for WT and 
AMPKα1 (-/-) mice. Percentage of plantaris muscles mass increase following 7 and 21 days 
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of overload in WT and AMPKα1 (-/-) mice relative to day 0 counterparts is presented on the 
right part of the figure (Inset). Results are represented as means ± SD, n = 6 for each group. 
Different from Day 0 : 
$
 P<0.05, 
$$
P<0.01; Different from WT : 
###
P<0.001. Frequency 
distribution of cross sectional area fibers in plantaris muscle from WT and AMPKα1 (-/-) 
mice before (B) and after 7 days (C) and 21 days (D) of overload. The fiber cross-sectional 
area of 318 fibers was determined from at least 9 different muscle areas of 3-6 animals in each 
group. Results are represented as means ± SD. Different from WT : 
#
P<0.05, 
##
P<0.01, 
###
P<0.001. 
 
Figure 6 : Changes in phosphorylation levels of p70S6K, S6K, 4E-BP1 and eEF2 in 
plantaris muscle following overload-induced hypertrophy in WT and AMPKα1 (-/-) 
mice. (A) p70S6K phosphorylation at Thr389 (upper part) and S6 ribosomal protein 
phosphorylation at Ser235/236 (lower part) measured by western blot analysis in plantaris 
muscle before (D0) and following 7 (D7) and 21 (D21) days of overload. (B) 4E-BP1 
phosphorylation at Thr37/46 (upper part) and eEF2 phophorylation at Thr56 (lower part) 
measured by western blot analysis in plantaris muscle before (D0) and following 7 (D7) and 
21 (D21) days of overload. Quantification by densitometry of all immunoblots is reported 
alonside the figure. Results are represented as means ± SD, n = 4 for each genotype. Different 
from Day 0 : 
$
P<0.05, 
$$
P<0.01, 
$$$
P<0.001; Different from WT : 
#
P<0.05, 
##
P<0.01, 
###
P<0.001. 
